SC 13G/A: Viridian Therapeutics, Inc.\DE

AI Summary

SC 13G/A filing by Viridian Therapeutics, Inc.\DE.

Risk Assessment

Risk Level: low

Key Financial Figures

• $0.01 — Inc. (Name of Issuer) Common Stock, $0.01 par value (Title of Class of Securiti

Filing Documents

• tm2428137d19_sc13ga.htm (SC 13G/A) — 150KB
• 0001104659-24-119339.txt ( ) — 152KB

From the Filing

SC 13G/A 1 tm2428137d19_sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 4)* Viridian Therapeutics, Inc. (Name of Issuer) Common Stock, $0.01 par value (Title of Class of Securities) 92790C104 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of This Check the appropriate box to designate the rule pursuant to which this Schedule is filed: Rule 13d-1(b) Rule 13d-1(c) Rule 13d-1(d) * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). CUSIP No. 92790C104 Page 2 of 14 1. Name of reporting persons Venrock Healthcare Capital Partners III, L.P. 2. Check the Appropriate Box if a Member of a Group (See Instructions) (a) (1) (b) 3. SEC USE ONLY 4. Citizenship or Place of Organization Delaware Number of Shares Beneficially Owned by Each Reporting Person With: 5. Sole Voting Power 0 6. Shared Voting Power 3,575,309 (2) 7. Sole Dispositive Power 0 8. Shared Dispositive Power 3,575,309 (2) 9. Aggregate Amount Beneficially Owned by Each Reporting Person 3,575,309 (2) 10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) 11. Percent of Class Represented by Amount in Row (9) 5.5% (3) 12. Type of Reporting Person (See Instructions) PN (1) This Schedule 13G/A is being filed by (i) Venrock Healthcare Capital Partners III, L.P. ("VHCP-III"), VHCP Co-Investment Holdings III, LLC ("VHCP-III Co-Invest"), Venrock Healthcare Capital Partners EG, L.P. ("VHCP-EG"), VHCP Management III, LLC, the general partner of VHCP-III and the manager of VHCP-III Co-Invest ("VHCPM-III"), VHCP Management EG, LLC (VHCPM-EG"), the general partner of VHCP-EG, Nimish Shah ("Shah") and Bong Koh ("Koh" and together with VHCP-III, VCHCP-III Co-Invest, VHCP-EG, VHCPM-III and Shah, the "Reporting Persons."). The Reporting Persons are members of a group for the purposes of this Schedule 13G/A. (2) Consists of (i) 941,675 shares of common stock and 313,883 shares of common stock issuable upon the conversion of Series A preferred stock and/or Series B preferred stock held by VHCP-III, (ii) 94,046 shares of common stock and 31,471 shares of common stock issuable upon the conversion of Series A preferred stock and/or Series B preferred stock held by VHCP-III Co-Invest and (iii) 1,494,666 shares of common stock and 699,568 shares of common stock issuable upon the conversion of Series A preferred stock and/or Series B preferred stock held by VHCP-EG. (3) This percentage is calculated based upon the sum of (i) 63,889,920 shares of the Issuer's common stock outstanding as of August 5, 2024 as reported in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (the " SEC ") on August 8, 2024 and (ii) 1,044,922 shares of common stock issuable upon conversion of Series A preferred stock and/or Series B preferred stock held by the Reporting Persons. CUSIP No. 92790C104 Page 3 of 14 1. Name of reporting persons VHCP Co-Investment Holdings III, LLC 2. Check the Appropriate Box if a Member of a Group (See Instructions) (a) (1) (b) 3. SEC USE ONLY 4. Citizenship or Place of Organization Delaware Number of Shares Beneficially Owned by Each Reporting Person With: 5. Sole Voting Power 0 6. Shared Voting Power 3,575,309 (2) 7. Sole Dispositive Power 0 8. Shared Dispositive Power 3,575,309 (2) 9. Aggregate Amount Beneficially Owned by Each Reporting Person 3,575,309 (2) 10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) 11. Percent of Class Represented by Amount in Row (9) 5.5% (3) 12. Type of Reporting Person (See Instructions) OO (1) This Schedule 13G/A is being filed by (i) Venrock Healthcare Capital Partners III, L.P. ("VHCP-III"), VHCP Co-Investment Holdings III, LLC ("VHCP-III Co-Invest"), Venrock Healthcare Capital Partners EG, L.P. ("VHCP-EG"), VHCP Management III, LLC, the general partner of VHCP-III and the manager of VHCP-III Co-Invest ("VHCPM-III"), VHCP Management EG, LLC (VHCPM-EG"), the general partner of VHCP-EG, Nimish Shah ("Shah") and Bong Koh ("Koh" and together with VHCP-III, VCHCP-III Co-Invest, VHCP-EG, VHCPM-III and Shah, the "Reporting Persons."). The Reporting Persons are

View Full Filing

View this SC 13G/A filing on SEC EDGAR